NASDAQ:CRVS

Corvus Pharmaceuticals - CRVS Stock Forecast, Price & News

$1.02

+0.05 (+5.15%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.91
▼
$1.04
50-Day Range: $0.71
▼
$1.02
52-Week Range: $0.70
▼
$3.41

Volume: 231,573 shs
Average Volume: 121,650 shs
Market Capitalization: $47.48 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Corvus Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 292.2% Upside
$4.00 Price Target
Short Interest: Healthy
0.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$35,200 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.92) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

220th out of 1,034 stocks

Pharmaceutical Preparations Industry

89th out of 502 stocks

3.5

Analyst's Opinion

Consensus Rating
Corvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Corvus Pharmaceuticals has a forecasted upside of 292.2% from its current price of $1.02.
Amount of Analyst Coverage
Corvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.60% of the float of Corvus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Corvus Pharmaceuticals has recently decreased by 0.48%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Corvus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corvus Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CRVS.

0.6

News and Social Media Coverage

Search Interest
13 people have searched for CRVS on MarketBeat in the last 30 days.
MarketBeat Follows
Only 3 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corvus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
29.70% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
55.02% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.92) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corvus Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corvus Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corvus Pharmaceuticals has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corvus Pharmaceuticals (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

November 14, 2022 | finance.yahoo.com

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

November 4, 2022 | apnews.com

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

November 4, 2022 | finanznachrichten.de

Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

November 4, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

November 3, 2022 | finance.yahoo.com

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

November 2, 2022 | msn.com

Earnings Preview For Corvus Pharmaceuticals

October 27, 2022 | finance.yahoo.com

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

October 25, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

September 27, 2022 | finance.yahoo.com

Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer

September 26, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

September 15, 2022 | nasdaq.com

A number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholders

September 6, 2022 | finance.yahoo.com

Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 26, 2022 | finance.yahoo.com

Great news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last year

August 11, 2022 | finance.yahoo.com

Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade

August 8, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

August 8, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

July 28, 2022 | finance.yahoo.com

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022

July 21, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

May 10, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

May 7, 2022 | ca.finance.yahoo.com

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

May 5, 2022 | apnews.com

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

May 5, 2022 | finance.yahoo.com

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

April 26, 2022 | finance.yahoo.com

Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

March 19, 2022 | finance.yahoo.com

Leiv Lea Is The Chief Financial Officer of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) And They Just Picked Up 25% More Shares

March 10, 2022 | seekingalpha.com

Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Company Calendar

Last Earnings: 11/03/2022
Today: 12/04/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/09/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRVS
CUSIP: N/A
CIK: 1626971
Web: www.corvuspharma.com
Phone: (650) 900-4520
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +292.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.88)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,240,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.08%
Return on Assets: -42.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.67
Quick Ratio: 3.67

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.39 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 46,550,000
Free Float: 32,727,000
Market Cap: $47.48 million
Optionable: Not Optionable
Beta: 0.97

Key Executives

Dr. Richard A. Miller M.D. (Age 71)
Co-Founder, Pres, CEO & Chairman
Comp: $303k

Dr. Peter A. Thompson FACP (Age 62)
M.D., Co-Founder & Independent Director
Comp: $47k

Mr. Leiv Lea (Age 68)
Chief Financial Officer
Comp: $449k

Dr. William Benton Jones Ph.D. (Age 56)
Sr. VP of Pharmaceutical Devel.
Comp: $400.4k

Dr. Erik J. Verner Ph.D. (Age 57)
Co-Founder

Dr. James T. Rosenbaum M.D.
Sr. VP of Research

Mr. Alan C. Mendelson Esq.
Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRVS Stock - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRVS shares.
View CRVS analyst ratings or view top-rated stocks.
What is Corvus Pharmaceuticals' stock price forecast for 2023?: 3 Wall Street research analysts have issued 1-year price objectives for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 292.2% from the stock's current price.
View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts.
How have CRVS shares performed in 2022?: Corvus Pharmaceuticals' stock was trading at $2.41 at the beginning of the year. Since then, CRVS shares have decreased by 57.7% and is now trading at $1.02.
View the best growth stocks for 2022 here.
When is Corvus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CRVS earnings forecast.
How were Corvus Pharmaceuticals' earnings last quarter?: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Thursday, November, 3rd. The company reported ($0.32) earnings per share for the quarter.
What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?: 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).
When did Corvus Pharmaceuticals IPO?: (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
What is Corvus Pharmaceuticals' stock symbol?: Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
Who are Corvus Pharmaceuticals' major shareholders?: Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.10%), Telemetry Investments L.L.C. (1.12%), Two Sigma Advisers LP (1.03%), Two Sigma Investments LP (0.92%), Bailard Inc. (0.09%) and Dimensional Fund Advisors LP (0.08%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends.
How do I buy shares of Corvus Pharmaceuticals?: Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Corvus Pharmaceuticals' stock price today?: One share of CRVS stock can currently be purchased for approximately $1.02.
How much money does Corvus Pharmaceuticals make?: Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $47.48 million. The company earns $-43,240,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.
How can I contact Corvus Pharmaceuticals?: Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com.

This page (NASDAQ:CRVS) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial